The FDA prefers trials to conducted in regions with a relevant population.
So if you are trialing a treatment with the intention of getting regulatory approval to market it in the US, you should conduct your trial on the representative target population in the US rather than say Japan or Nigeria.
Not unreasonable.
Ann: S&P DJI Announces September 2021 Quarterly Rebalance, page-49
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
